We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+33.1%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$195M
Cap. Flow
+$52.3M
Cap. Flow %
6.9%
Top 10 Hldgs %
45.66%
Holding
77
New
20
Increased
20
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.6M
2
WINT
Windtree Therapeutics Inc
WINT
+$13.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$10.9M
5
DVAX
Dynavax Technologies
DVAX
+$10.6M

Top Sells

Rank Stock Value
1
NTUS
Natus Medical Inc
NTUS
+$29.1M
2
ALKS icon
Alkermes
ALKS
+$15.1M
3
IART icon
Integra LifeSciences
IART
+$8.91M
4
SPNC
Spectranetics Corp
SPNC
+$8.33M
5
NUVA
NuVasive, Inc.
NUVA
+$7.35M

Sector Composition

Rank Sector Weight
1 Healthcare 76.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBST
76
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-25,000
Closed -$1.59M
FRX
77
DELISTED
FOREST LABORATORIES INC
FRX
– –
-50,000
Closed -$2.14M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Broadfin Capital held 77 positions worth $758M, up 35% from $563M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Broadfin Capital deployed $52.3M of net new capital in Q4 2013, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 726,655 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was Natus Medical Inc, an estimated $29.1M trimmed.

  • Broadfin Capital's largest Q4 2013 buy was Sarepta Therapeutics: 726,655 shares worth $14.8M.
  • Broadfin Capital added most to Windtree Therapeutics Inc in Q4 2013, an estimated $13.2M increase.
  • Broadfin Capital's biggest Q4 2013 reduction was Natus Medical Inc, cutting an estimated $29.1M.
  • Broadfin Capital fully exited Alkermes in Q4 2013, selling an estimated $15.1M.
  • Broadfin Capital's ten largest holdings make up 46% of its $758M portfolio in Q4 2013.
  • Broadfin Capital opened 20 new positions and closed 17 in Q4 2013.
  • Broadfin Capital's portfolio value rose 35% quarter-over-quarter to $758M.

Based on Broadfin Capital's 13F filing for Q4 2013, filed 14 Feb 2014.